Research Topics
Genomes and Genes | Holger NuckelSummaryAffiliation: University Hospital Country: Germany Publications
| Collaborators
|
Detail Information
Publications
HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemiaHolger Nuckel
Department of Hematology, University of Duisburg Essen, Germany
Blood 105:1694-8. 2005..HLA-G may contribute to the impairment of immune responses against tumor cells and infections. Thus, these findings need to be confirmed in a prospective study...
FCRL2 mRNA expression is inversely associated with clinical progression in chronic lymphocytic leukemiaHolger Nuckel
Department of Hematology, University of Duisburg Essen, Germany
Eur J Haematol 83:541-9. 2009..In multivariate analysis low FCRL2 expression was a significant independent prognostic factor (HR 2.4; P = 0.005). Here we demonstrate that the level of FCRL2 expression is correlated with prognosis in B-CLL...- Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemiaHolger Nuckel
Department of Hematology, Medical Faculty, University of Duisburg Essen, Germany
Blood 109:290-7. 2007..034) together with disease stage at diagnosis (HR 2.5; P = .004) and ZAP-70 status (HR 3.0; P = .001). The BCL2-938AA genotype is associated with increased Bcl-2 expression and a novel unfavorable genetic marker in patients with B-CLL... - p53 protein expression in chronic lymphocytic leukemiaLudger Sellmann
Department of Hematology, Medical Faculty, University of Duisburg Essen, Essen, Germany
Leuk Lymphoma 53:1282-8. 2012..Taken together, the differential expression of p53 isoforms could disrupt the p53 response and contribute to CLL pathogenesis... - The G-Allele of the PSMA6-8C>G polymorphism is associated with poor outcome in multiple myeloma independently of circulating proteasome serum levelsHagen S Bachmann
Institute of Pharmacogenetics, Medical Faculty, University of Duisburg Essen, Duisburg, Germany
Eur J Haematol 85:108-13. 2010..Moreover, PSMA6 mRNA expression in human B-cell lines depended on genotypes. We investigated a potential role of this novel SNP in patients with MM... - The AA genotype of the regulatory BCL2 promoter polymorphism ( 938C>A) is associated with a favorable outcome in lymph node negative invasive breast cancer patientsHagen S Bachmann
Institute of Pharmacogenetics, University of Duisburg Essen, Germany
Clin Cancer Res 13:5790-7. 2007..We recently showed a novel regulatory (-938C>A) single-nucleotide polymorphism (SNP) in the inhibitory P2 BCL2 gene promoter generating significantly different BCL2 promoter activities... - Telomeres and prognosis in patients with chronic lymphocytic leukaemiaLudger Sellmann
Department of Haematology, University of Duisburg Essen, Essen, Germany
Int J Hematol 93:74-82. 2011..Short telomeres and high telomerase activity as occurs in some patients with CLL with a worse prognosis might be an ideal target for treatment with telomerase inhibitors... - Association of the CC genotype of the regulatory BCL2 promoter polymorphism (-938C>A) with better 2-year survival in patients with glioblastoma multiformeNicolai El Hindy
Department of Neurosurgery, Medical Faculty, University of Duisburg Essen, Essen, Germany
J Neurosurg 114:1631-9. 2011..The authors investigated the role of a common regulatory single-nucleotide polymorphism (-938C>A), which is located in the inhibitory P2 promoter of BCL2... - High CD49d protein and mRNA expression predicts poor outcome in chronic lymphocytic leukemiaHolger Nuckel
Department of Haematology, University of Duisburg Essen, Germany
Clin Immunol 131:472-80. 2009..Collectively, our data confirm the prognostic significance supporting the idea to use CD49d as target molecules for therapeutic approaches in B-CLL... - Investigating the role of CD38 and functionally related molecular risk factors in the CLL NOD/SCID xenograft modelSemra Aydin
Department of Hematology, University of Duisburg Essen Medical School, Essen, Germany
Eur J Haematol 87:10-9. 2011..This model could be useful for evaluating the biological basis of CLL growth in the context of the hematopoietic microenvironment as well as preclinical testing of novel compounds... - Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicityHolger Nuckel
Department of Hematology, Medical School, University of Duisburg Essen, Germany
Eur J Pharmacol 514:217-24. 2005..Alemtuzumab significantly enhances apoptosis in chronic lymphocytic leukemia cells in vitro, especially in combination with a cross-linking anti-Fc-antibody, this effect being mediated by a caspase-dependent pathway... - Combined PER2 and CRY1 expression predicts outcome in chronic lymphocytic leukemiaLewin Eisele
Department of Hematology, University Hospital, Hufelandstrasse 55, Essen, Germany
Eur J Haematol 83:320-7. 2009..Because of their role in the expression of cell cycle-related and DNA-damage response genes, we suggest that the deregulated expression of circadian genes may be linked to the molecular pathogenesis of CLL... - Prognostic significance of serum cystatin C in multiple myelomaHolger Nuckel
Department of Hematology, University Hospital Essen, Hufelandstr 55, 45122, Essen, Germany
Int J Hematol 95:545-50. 2012..The level of serum cystatin C is not only a sensitive marker of renal function, but also reflects tumor burden and delivers prognostic information in MM... - Gene dosage effects in chronic lymphocytic leukemiaLudger Sellmann
Department of Hematology, Medical Faculty, University of Duisburg Essen, Hufelandstrase 55, 45122 Essen, Germany
Cancer Genet Cytogenet 203:149-60. 2010..We did not confirm a consistent correlation between MIRN15A and MIRN16-1 expression levels and BCL2 protein levels, indicating a complex regulation of BCL2 expression... - Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patientsSemra Aydin
Department of Hematology, Medical Faculty, University of Duisburg Essen, Essen, Germany
Ann Hematol 86:271-6. 2007.... - Trisomy 19 is associated with trisomy 12 and mutated IGHV genes in B-chronic lymphocytic leukaemiaLudger Sellmann
Department of Haematology, Medical Faculty, University of Duisburg Essen, Essen, Germany
Br J Haematol 138:217-20. 2007..Karyotypes of the present study and the literature identified a strong correlation to trisomy 18 in addition to trisomy 12. Trisomy 19 seems to be a secondary event in B-CLL with trisomy 12, mostly originating from mutated B cells... - Lipoprotein lipase expression is a novel prognostic factor in B-cell chronic lymphocytic leukemiaHolger Nuckel
Department of Hematology, University Hospital Essen, Essen, Germany
Leuk Lymphoma 47:1053-61. 2006..The LPL/ADAM29 expression ratio was not found to be an independent prognostic factor and did not offer any advantages over the use of LPL alone. Collectively, our data confirm a role for LPL as a novel prognostic indicator in B-CLL... - 1513A/C polymorphism in the P2X7 receptor gene in chronic lymphocytic leukemia: absence of correlation with clinical outcomeHolger Nuckel
Department of Hematology, Medical Faculty, University of Essen, Essen, Germany
Eur J Haematol 72:259-63. 2004..In conclusion, our data do not support a role of the P2X7 genotype as a prognostic marker in B-cell CLL... - Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctivaHolger Nuckel
Department of Hematology, Medical Faculty, University of Essen, Germany
Eur J Haematol 73:258-62. 2004..Rituximab is a highly effective and well-tolerated treatment of conjunctival MALT lymphoma, which may not only be of value in relapse, but also in cases of contraindication to radiotherapy...